Deproteinized Calf Blood Extractives, as a drug that improves the energy metabolism of cells, has aroused wide concern at home and abroad after years of clinical application because of its prominent curative effect on the nervous system. At present, the clinical applications mainly include cerebral and nervous system diseases, vascular diseases, ulcer diseases, burns, etc.
The global growth of patented nervous system drugs is slowing down. The drugs used to treat cranial nerve and cerebral circulation systems are experiencing a market downturn. However, the market performance is quite different in China. In recent years, the drug demand from neurology departments of Chinese hospitals is growing continuously with the rapid development of the pathogenesis of common neurological diseases and clinical pharmacology. Deproteinized Calf Blood Extractives is a big variety and also a pillar nervous system drug in clinical applications in China.
According to CRI, the sales value of Deproteinized Calf Blood Extractives exceeded CNY 1 billion in 2017. The market was dominated by Jinzhou Ahon Pharmaceuticals Co., Ltd., Harbin Sanctity Pharmaceutical Co., Ltd., Jilin Connell Pharmaceutical Co., Ltd., Wuhan Humanwell Pharmaceutical Co., Ltd., etc., with CR5 reaching over 90%. Jinzhou Ahon Pharmaceuticals Co., Ltd. captured the biggest market share, whose market share exceeded 70% by sales value in 2017.
Injections account for over 90% of the sales value while the market shares of gels and eye drops are less than 5% in total.
CRI expects that the Chinese Deproteinized Calf Blood Extractives market still has some growth potential from 2018 to 2022.
-Development environment of the Chinese Deproteinized Calf Blood Extractives market
-Size of the Chinese Deproteinized Calf Blood Extractives market
-Competition pattern of the Chinese Deproteinized Calf Blood Extractives market
-Prices in the Chinese Deproteinized Calf Blood Extractives market
-Forecast on the Chinese Deproteinized Calf Blood Extractives market